MedPath

Paroxetine

Generic Name
Paroxetine
Brand Names
Paxil, Pexeva
Drug Type
Small Molecule
Chemical Formula
C19H20FNO3
CAS Number
61869-08-7
Unique Ingredient Identifier
41VRH5220H
Background

Paroxetine is a selective serotonin reuptake inhibitor (SSRI) drug commonly known as Paxil. It has a variety of uses, including the treatment of anxiety disorders, major depression, posttraumatic stress disorder, and symptoms of menopause, among others. It was approved by the FDA in the early 1990s and marketed by SmithKline Beecham. A unique feature of this drug is that it is highly potent and selective in its inhibition of serotonin reuptake and has little effect on other neurotransmitters. Because of its potent inhibition of serotonin reuptake, paroxetine is more likely to cause withdrawal effects upon cessation. Paroxetine is well tolerated in most patients with a similar adverse effect profile to other members of its drug class. The controlled release formulation was designed to decrease the likelihood of nausea that is sometimes associated with paroxetine.

Indication

Paroxetine is indicated for the management of depression, obsessive-compulsive disorder, panic disorder, social anxiety disorder, generalized anxiety disorder, posttraumatic stress disorder. One form of paroxetine, commercially known as Brisdelle, is used to manage mild to moderate vasomotor symptoms of menopause. Off-label, paroxetine may be used for the treatment of premature ejaculation or irritable bowel syndrome (IBS).

Associated Conditions
Generalized Anxiety Disorder, Irritable Bowel Syndrome (IBS), Major Depressive Disorder (MDD), Obsessive Compulsive Disorder (OCD), Panic Disorder, Post Traumatic Stress Disorder (PTSD), Premature Ejaculation, Premenstrual Dysphoric Disorder (PMDD), Social Anxiety Disorder (SAD), Vasomotor Symptoms Associated With Menopause

Definitive Selection of Neuroimaging Biomarkers for the Diagnosis and Treatment to Common Mental Disorders

Not Applicable
Completed
Conditions
Common Mental Disorder
Interventions
Drug: Antipsychotic drugs
Drug: Mood stabilizer
First Posted Date
2020-01-06
Last Posted Date
2024-08-21
Lead Sponsor
Central South University
Target Recruit Count
200
Registration Number
NCT04218981
Locations
🇨🇳

The Second Xiangya Hospital of Central South University, Changsha, China

Transcutaneous Posterior Tibial Nerve Stimulation for Premature Ejaculation

Not Applicable
Recruiting
Conditions
Premature Ejaculation
Interventions
Other: Transcutaneous posterior tibial nerve stimulation
First Posted Date
2019-12-23
Last Posted Date
2025-02-04
Lead Sponsor
Boston Medical Group
Target Recruit Count
120
Registration Number
NCT04207723
Locations
🇨🇴

Boston Medical Group, Bogotá, Colombia

Endobiotics for Phenotyping of Human Cytochrome P450 Enzymes

First Posted Date
2019-12-05
Last Posted Date
2022-01-04
Lead Sponsor
Jules Desmeules
Target Recruit Count
40
Registration Number
NCT04188028
Locations
🇨🇭

HUG, Geneva, Switzerland

Definitive Selection of Neuroimaging Biomarkers in Anxiety Disorder and Obsessive-compulsive Disorder: A Longitudinal Functional Magnetic Resonance Imaging (fMRI) Study With Paroxetine Treatment

Not Applicable
Completed
Conditions
Anxiety Disorder
Obsessive-Compulsive Disorder
Interventions
First Posted Date
2019-03-28
Last Posted Date
2024-08-21
Lead Sponsor
Central South University
Target Recruit Count
150
Registration Number
NCT03894085
Locations
🇨🇳

The Second Xiangya Hospital of Central South University, Changsha, China

Effect of Tamsulosin on PE Compared With Paroxetine Hydrochloride

Phase 3
Conditions
Premature Ejaculation
Interventions
First Posted Date
2019-03-19
Last Posted Date
2019-03-19
Lead Sponsor
Assiut University
Target Recruit Count
160
Registration Number
NCT03879746

Vortioxetine in the Elderly vs. Selective Serotonin Reuptake Inhibitors (SSRIs): a Pragmatic Assessment

First Posted Date
2018-12-19
Last Posted Date
2023-05-19
Lead Sponsor
Azienda Ospedaliera Universitaria Integrata Verona
Target Recruit Count
362
Registration Number
NCT03779789
Locations
🇮🇹

Azienda Ospedaliera Universitaria Mater Domini, Università Magna Grecia, Catanzaro, Italy

🇮🇹

Sapienza Università di Roma, Dipartimento di Neurologia e Psichiatria, Roma, Italy

🇮🇹

Azienda Ospedaliera Universitaria Verona, Verona, Italy

Bioequivalence Study of Paroxetine Tablets and Paxil® Under Fasting and Fed Conditions in Chinese Healthy Volunteers

Phase 1
Completed
Conditions
Major Depressive Disorder
Panic Disorder
Obsessive-Compulsive Disorder
Social Anxiety Disorder
Generalized Anxiety Disorder
Interventions
First Posted Date
2018-04-20
Last Posted Date
2018-12-19
Lead Sponsor
Beijing Tongren Hospital
Target Recruit Count
53
Registration Number
NCT03504475
Locations
🇨🇳

Beijing TongRen Hospital, Beijing, China

Bioequivalence Study of Paroxetine Immediate Release (IR) Tablets Manufactured in GlaxoSmithKline Tianjin (GSKT) and Mississauga Sites in Healthy Chinese Subjects

Phase 1
Completed
Conditions
Anxiety Disorders
Interventions
First Posted Date
2017-11-06
Last Posted Date
2020-03-27
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
85
Registration Number
NCT03329573
Locations
🇨🇳

GSK Investigational Site, Shanghai, China

Psycho-biological Substrates of Therapeutic Benefit of Thermal Cure on Generalized Anxiety Disorders

Phase 4
Completed
Conditions
Generalized Anxious Disorders
Interventions
Other: Thermal cure
First Posted Date
2017-09-11
Last Posted Date
2022-10-12
Lead Sponsor
Centre Hospitalier Henri Laborit
Target Recruit Count
52
Registration Number
NCT03277339
Locations
🇫🇷

Centre Hospitalier Henri Laborit, Poitiers, France

🇫🇷

Les thermes de Saujon, Saujon, France

© Copyright 2025. All Rights Reserved by MedPath